

Certificate of Analysis

Print Date: May 14th 2021

www.tocris.com

Product Name: LY 288513 Catalog No.: 1524 Batch No.: 3

CAS Number: 147523-65-7

IUPAC Name: (4S,5R)-N-(4-Bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₂₂H₁₈BrN₃O₂.½H₂O

Batch Molecular Weight: 440.8

Physical Appearance: White solid

Solubility: DMSO to 100 mM Storage: Store at +4°C

Batch Molecular Structure:

2. ANALYTICAL DATA

HPLC: Shows 98.9% purity

¹H NMR: Consistent with structure Mass Spectrum: Consistent with structure

Optical Rotation: $[\alpha]_D = +47.9$ (Concentration = 1, Solvent = Chloroform)

Microanalysis: Carbon Hydrogen Nitrogen

Theoretical 59.94 4.23 9.53 Found 59.97 4.14 9.56



Product Information

Print Date: May 14th 2021

www.tocris.com

Product Name: LY 288513 Catalog No.: 1524 Batch No.: 3

CAS Number: 147523-65-7

IUPAC Name: (4S,5R)-N-(4-Bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide

Description:

Selective CCK_2 receptor antagonist (IC_{50} values are 16 and > 30,000 nM for CCK_2 and CCK_1 respectively). Displays anxiolytic and antipsychotic properties in vivo.

Physical and Chemical Properties:

Batch Molecular Formula: C₂₂H₁₈BrN₃O₂.½H₂O

Batch Molecular Weight: 440.8 Physical Appearance: White solid

Minimum Purity: ≥98%

Batch Molecular Structure:

Storage: Store at +4°C

Solubility & Usage Info:

DMSO to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Licensing Information:

Sold with the permission of Eli Lilly and Company

References:

Helton *et al* (1996) Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol.Biochem.Behav. *53* 493. PMID: 8866946.

Rasmussen (1994) CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain DA neurons. Ann.N.Y.Acad.Sci. 713 300. PMID: 8185172.

Rasmussen et al (1992) Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain DA neurons. J.Pharmacol.Exp.Ther. **264** 480.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use